Literature DB >> 33875427

Evaluation of Total Body Weight versus Adjusted Body Weight Voriconazole Dosing in Obese Patients.

Elizabeth Diller1, Tamara Krekel1, Andrej Spec2, Jeff Klaus1.   

Abstract

This retrospective single-center study of a cohort of adult patients who received voriconazole with a steady-state trough concentration measured during therapy evaluated the rate of therapeutic trough attainment using adjusted body weight (AdjBW)-based and total body weight (TBW)-based dosing in overweight and obese patients. Of the 130 patients included, 45 patients received TBW-based dosing and 85 patients received AdjBW-based dosing. Therapeutic trough attainment was significantly improved with AdjBW-based dosing compared to TBW-based dosing (64.7% versus 46.7%; P = 0.047).

Entities:  

Keywords:  anti-infection agents; antifungal therapy; azole antifungals; azoles; drug monitoring; fungal infections; obesity; therapeutic drug monitoring; voriconazole

Mesh:

Substances:

Year:  2021        PMID: 33875427      PMCID: PMC8218689          DOI: 10.1128/AAC.02460-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Steady-state plasma pharmacokinetics of oral voriconazole in obese adults.

Authors:  Manjunath P Pai; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

2.  Obesity: preventing and managing the global epidemic. Report of a WHO consultation.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  2000

3.  Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-08-15       Impact factor: 9.079

Review 4.  Drug dosing in obese adults.

Authors:  Michael Barras; Amy Legg
Journal:  Aust Prescr       Date:  2017-10-03

5.  Therapeutic drug monitoring and use of an adjusted body weight strategy for high-dose voriconazole therapy.

Authors:  Patrick G Richards; Kimberlyn M Dang; Carol A Kauffman; Kay Lyn Stalker; David Sudekum; Lisa Kerr; Michelle Brinker-Bodley; Beena Cheriyan; Nina West; Curtis D Collins; Shikha Polega; Anurag N Malani
Journal:  J Antimicrob Chemother       Date:  2017-04-01       Impact factor: 5.790

6.  The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.

Authors:  Wan Beom Park; Nak-Hyun Kim; Kye-Hyung Kim; Seung Hwan Lee; Won-Seok Nam; Seo Hyun Yoon; Kyoung-Ho Song; Pyoeng Gyun Choe; Nam Joong Kim; In-Jin Jang; Myoung-Don Oh; Kyung-Sang Yu
Journal:  Clin Infect Dis       Date:  2012-07-03       Impact factor: 9.079

Review 7.  Voriconazole.

Authors:  LilyAnn Jeu; Frank J Piacenti; Aleksandr G Lyakhovetskiy; Horatio B Fung
Journal:  Clin Ther       Date:  2003-05       Impact factor: 3.393

8.  Evaluation of the effect of obesity on voriconazole serum concentrations.

Authors:  Elizabeth Koselke; Shawna Kraft; Jeannina Smith; Jerod Nagel
Journal:  J Antimicrob Chemother       Date:  2012-08-21       Impact factor: 5.790

9.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

Authors:  Andres Pascual; Thierry Calandra; Saskia Bolay; Thierry Buclin; Jacques Bille; Oscar Marchetti
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

Review 10.  Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review.

Authors:  Samantha Davies-Vorbrodt; James I Ito; Bernard R Tegtmeier; Sanjeet S Dadwal; Jane Kriengkauykiat
Journal:  Pharmacotherapy       Date:  2013-01       Impact factor: 4.705

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.